Pharmaceutical giant Astra Zeneca reported a 10 percent increase in revenue at constant currency rates in the third quarter compared to the same quarter last year. Revenue was $15.2 billion.
Earnings were $2.38 per share, 12 percent higher than last year at constant exchange rates.
"The strong underlying growth rate across the business during the first nine months of this year gives us good conditions to maintain growth in 2026 and means that we are in line with our goals for 2030," writes the company's CEO Pascal Soriot in the interim report.
